Phio Posts Wider Loss in Fiscal Q2

Phio Pharmaceuticals (NASDAQ:PHIO), a biotechnology company developing gene-silencing therapies for cancer, released its second quarter 2025 results on August 14, 2025. The quarter’s key news included a GAAP EPS of $(0.45), missing the consensus GAAP estimate of $(0.36) by $0.09. GAAP net loss increased to $2.2 million as operating expenses rose alongside clinical trial expansion. GAAP revenue held at $0, This met analyst expectations. The quarter showed significant advancement of the INTASYL platform and the PH-762 program, despite the elevated expenses and continuing absence of product revenue.

Source: Analyst estimates for the quarter provided by FactSet.

Phio Pharmaceuticals is focused on developing next-generation cancer therapies using its proprietary INTASYL technology. The INTASYL platform enables the silencing of specific genes used by cancer cells to escape the immune system. This approach does not require specialized delivery systems, allowing for a broad application across different types of cells and tissues.

Continue reading

Source Fool.com